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Review Article
High-Grade Prostatic Intraepithelial Neoplasia
Joseph C Klink, Ranko Miocinovic, Cristina Magi Galluzzi, Eric A Klein
Glickman Urologic and Kidney Institute, Cleveland, Ohio, USA 
High-grade prostatic intraepithelial neoplasia (HGPIN) has been established as a pre-
cursor to prostatic adenocarcinoma. HGPIN shares many morphological, genetic, and 
molecular signatures with prostate cancer. Its predictive value for the development of 
future adenocarcinoma during the prostate-specific antigen screening era has de-
creased, mostly owing to the increase in prostate biopsy cores. Nevertheless, a literature 
review supports that large-volume HGPIN and multiple cores of involvement at the 
initial biopsy should prompt a repeat biopsy of the prostate within 1 year. No treatment 
is recommended for HGPIN to slow its progression to cancer. 
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INTRODUCTION
The era of prostate-specific antigen (PSA) screening has re-
sulted in an increase in the number of prostate biopsies be-
ing performed and as a result an increased detection of pro-
static intraepithelial neoplasia (PIN) on microscopic ex-
amination [1]. The specific diagnosis of PIN had histor-
ically created some debate and uncertainty in terms of its 
clinical significance and relationship to prostate cancer. 
However, more recent studies confirm that high-grade PIN 
(HGPIN) shares a clinical, morphological, and genetic 
background with prostate cancer. In the current report, we 
review the recent literature pertaining to this entity and 
the clinical recommendations once a diagnosis of HGPIN 
is established. 
EPIDEMIOLOGY
PIN, which was initially referred to as “intraductal dyspla-
sia,” was first described to be a direct biological precursor 
to prostatic adenocarcinoma by McNeal and Bostwick [2] 
in 1986. Although in the initial description of PIN the clas-
sification included three different grades of dysplasia, at 
the present time, only HGPIN is reported by pathologists. 
This is mostly the result of the poor reproducibility among 
pathologists of distinguishing between low-grade PIN and 
benign prostate tissue [1,3]. Numerous studies since the in-
itial description have confirmed HGPIN as an accepted 
precursor to some prostatic adenocarcinomas, and as such 
it has become a clinically important finding on prostate bi-
opsy in terms of possessing high predictive value for cancer 
[4]. The estimated time frame to disease progression after 
HGPIN findings has been reported to be between 29 and 
36 months [5,6]. In addition, an increase in the size and 
number of HGPIN foci has been associated with both pros-
tate adenocarcinoma and its multifocality [7-13]. HGPIN 
and carcinoma tend to preferentially involve the periph-
eral zone of the prostate [8,9], and recently many bio-
markers and molecular changes such as TMPRSS2-ERG 
gene fusion have been described in both entities (as dis-
cussed further below) [14,15]. 
The population incidence of HGPIN seems to parallel 
that of prostate adenocarcinoma. Previous autopsy studies 
revealed that HGPIN had a low prevalence in men during 
their third decade of life (7% in African Americans vs. 8% 
in Caucasians) and progressively increased with advanc-
ing age (91% in African Americans vs. 67% in Caucasians) 
[16]. Sakr et al. [16,17] also observed a higher prevalence 
of HGPIN in African Americans than in age-matched 
Caucasian men, similar to prostate cancer. However, the 
reported incidence of HGPIN in men participating in PSA 
screening after needle biopsy varies widely according to dif-
ferent series, ranging from 0 to 25% with a mean incidence 
of 7.7% [4,10,18,19]. Once again, these diverse findings Korean J Urol 2012;53:297-303
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may be explained by the subjectivity of individual patholo-
gists concerning what constitutes HGPIN and possibly by 
the technical aspects of tissue preparation [18]. 
The incidence of HGPIN in Asian men is similar to that 
in Western men. In a study of Korean men undergoing radi-
cal cystoprostatectomy, 21% of the men who had no pros-
tate cancer in the final pathology were actually discovered 
to have HGPIN. As in studies of other races, HGPIN did 
not correlate with PSA, tumor volume, stage, grade, surgi-
cal margins, or lymphovascular invasion [20]. Han et al. 
[20] also found that both Western and Korean men have 
high rates of PIN associated with prostate cancer in prosta-
tectomy specimens. In a study from Singapore consisting 
of 48 Chinese, 3 Malays, 2 Indians, and 3 other men with 
isolated HGPIN, 24% of those who underwent repeat biop-
sies had prostate cancer. The authors also observed that 
most cases of HGPIN affected only one core (79%), with 18% 
and 4% of cases affecting two and three cores, respectively 
[21].
HISTORY AND EVOLUTION OF THE DEFINITION 
OF HGPIN
Historically, isolated HGPIN on the initial core biopsy was 
reported to be associated with a very high risk of prostate 
cancer on the repeat biopsy, up to 80% in some series 
[5,18,22-24]. In the contemporary era, this risk seems to 
have decreased to approximately 24%, which is slightly 
higher than the 19% found after repeat biopsy for a benign 
diagnosis [5,18]. This decrease in the incidence of cancer 
following a diagnosis of HGPIN is likely related to the in-
crease in the number of needle core biopsies taken, which 
has improved the accuracy of the initial biopsy. As one 
would expect with a pre-malignant lesion, the rate of cancer 
detection on repeat biopsy has been strongly correlated 
with an increasing number of cores (≥2) containing 
HGPIN in the initial biopsy [7,12,13]. As a result, this has 
led to the recommendation of repeat prostate biopsy within 
1 year of such findings. Interestingly, neither the initial 
PSA level nor PSA velocity at the time of HGPIN discovery 
correlates with the risk of cancer on repeat biopsy [12,13]. 
Likewise, digital rectal examination, transrectal ultra-
sound, and other imaging studies have not been shown to 
be useful in detecting HGPIN [12,13]. 
MOLECULAR AND GENETIC ALTERATIONS
More than 50 genetic and molecular abnormalities have 
been associated with HGPIN. At least 10 of these changes 
are reported in both HGPIN and prostate cancer [25-33]. 
In addition, more than 36 genetic and molecular alter-
ations are intermediate between normal prostate and pros-
tate cancer [25]. This has led to multiple studies making 
the conclusion that “High-grade PIN is the most likely pre-
cursor of prostatic adenocarcinoma, according to virtually 
all available evidence” [10,34,35]. Two excellent reviews 
that list in great detail the known genetic and molecular 
changes in HGPIN were published by Bostwick and Qian 
[25] and Mosquera et al. [33], and readers are encouraged 
to read them. 
The TMPRSS2-ERG gene fusion has been found in 30 to 
79% of prostate cancers [36] and is associated with ag-
gressive disease in some studies [37,38] but not in others 
[39]. This fusion has also been discovered in 16 to 19% of 
HGPIN lesions in patients with prostate cancer [15,33]. 
Because the cancer had the same fusion pattern as the 
HGPIN in all cases, it has been postulated that the HGPIN 
may be the premalignant lesion from which the cancer 
arose [33].
Multiple mechanisms leading to the dysregulation of cell 
proliferation and survival have been observed to be present 
in HGPIN. For example, overexpression of Prostate Tumor 
Overexpressed-1 contributes to cell proliferation in pros-
tate cancer. In HGPIN, it was shown to be an independent 
predictor of prostate cancer on repeat biopsy [40]. In addi-
tion, up-regulation of the mammalian target of rapamycin 
(mTOR) pathway promotes prostate cancer. A protein 
known as 14-3-3σ, which regulates the mTOR pathway, 
shows progressively increasing levels of expression from 
HGPIN through Gleason score 6, Gleason score 7, and 
high-grade prostate cancer [41]. The RER+ phenotype 
leads to the inactivation of many tumor suppressor genes. 
In one study, the RER+ phenotype was found in 4% of non-
cancerous prostate tissues, 16% of PIN lesions, and 42% of 
prostate cancer lesions [27]. The same study found micro-
satellite instability in 12%, 35%, and 53% of normal, PIN, 
and cancerous tissues. Fatty acid synthetase (FAS) ex-
pression, which is thought to be an early event in malignant 
transformation, has been shown to be overexpressed in 
HGPIN and prostate cancer, but no FAS expression was ob-
served in normal tissue [42]. Likewise, P53 mutations were 
detected in 14% of PIN and 25% of prostate cancer lesions 
in one study [43]. Bcl-2, a proto-oncogene that inhibits 
apoptosis, has been expressed in many prostate cancers, 
and has also been reported by Baltaci et al. [28] to be present 
in both low-grade PIN and HGPIN after immunohisto-
chemical evaluation.
Abnormalities in chromosomes, chromatin structure, 
and DNA processing enzymes have also been described in 
HGPIN. More than half of HGPIN lesions may have chro-
mosomal anomalies, including gains of chromosomes 
(decreasing order of frequency) 8, 10, 7, 12, and Y [26,29]. 
One study discovered loss of heterozygosity on chromo-
some 8p12-21 in 63% of PIN lesions in patients with pros-
tate cancer [26]. Telomerase, which can contribute to can-
cer cell immortalization, is active is some HGPIN foci [32]. 
DNA topoisomerase II-alpha staining by immunohisto-
chemistry is intermediate between benign tissue and pros-
tate cancer [30]. HGPIN also displays epigenetic changes, 
including hypermethylation [44].
HISTOPATHOLOGIC CHARACTERISTICS
HGPIN is characterized by a proliferation of secretory cells Korean J Urol 2012;53:297-303
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FIG. 1. Prostatic gland with HGPIN (right) and normal prostatic 
gland (left). Note the preserved architecture of the gland 
involved by HGPIN and largely intact basal cell layer (H&E, 
x20). HGPIN, high-grade prostatic intraepithelial neoplasia.
FIG. 2. High-power view of prostatic gland with HGPIN showing 
enlarged secretory cells with increased nuclear/cytoplasmic 
ratio and prominent nucleoli. Note the partially disrupted basal 
cell layer (H&E, x40). HGPIN, high-grade prostatic intraepi-
thelial neoplasia.
with significant cytologic atypia within the prostate glands 
and acini. The secretory cells are enlarged with an in-
creased nuclear/cytoplasmic ratio and prominent nucleoli 
(Fig. 1). The cytoplasm of the HGPIN cells tends to stain 
positively for α-methylacyl-CoA. Most of these features are 
shared by invasive prostate cancer [10,25,45]. However, in 
contrast to prostatic adenocarcinoma in which the basal 
cells are absent, in HGPIN the basal cell layer is retained 
although it is often discontinuous on hematoxylin and eo-
sin stain (Fig. 2) [45]. Immunohistochemical staining with 
antibodies to high molecular weight cytokeratins or nu-
clear p63 may help in the diagnosis because the presence 
of basal cells is easily demonstrated [10,19]. 
Four main architectural patterns of HGPIN have pre-
viously been described (tufting, micropapillary, cribri-
form, and flat), but these are thought to not differ clinically 
and differentiation seems to be of only diagnostic value 
[10,46]. 
DOES HGPIN PREDICT PROSTATE CANCER ON 
REPEAT BIOPSY?
Perhaps the most important question about HGPIN is 
whether its presence signals a higher risk of developing 
prostate cancer. For men who do not have cancer on pros-
tate biopsy, are those with HGPIN more likely to be diag-
nosed with prostate cancer in the future than are those with 
only benign tissue on the initial biopsy? Historically, the 
answer was “yes.” Prior to the era of intense PSA screening 
and before the implementation of extended prostate biopsy 
schemes, HGPIN indicated up to an 80% probability of find-
ing prostate cancer on additional biopsies [22]. At the time, 
it was astutely observed that “The finding of high-grade 
PIN on needle biopsy often represents a sampling problem 
with carcinoma nearby” [22]. Because the number of cores 
routinely sampled at prostate biopsy has increased, the 
predictive value of HGPIN for prostate cancer has 
decreased. In studies published before 2000, the prostate 
cancer detection rate was 36% on follow-up biopsy, but after 
2000, this rate dropped to 21% [47]. Another review of stud-
ies published after 2000 found the risk of cancer on sub-
sequent biopsy to be 5% lower for patients with HGPIN 
than for those with benign disease [18]. Two reviews by 
Bostwick et al. tabulate the details of multiple studies of 
the cancer detection rate in patients with HGPIN [25,48].
Several studies have shown that taking at least 8 cores 
on the initial biopsy leads to a low prostate cancer detection 
rate on repeat biopsy [49,50]. In men diagnosed with 
HGPIN during initial extended biopsies (at least 10 cores), 
taking more cores (at least 20) on repeat biopsies was an 
independent predictor of prostate cancer detection, after 
multivariate adjustment for age, PSA, days from initial bi-
opsy, DRE status, and multifocal PIN [51]. In-office 24-core 
saturation biopsy detects prostate cancer in 18% of men 
with HGPIN detected on a prior biopsy [52].
Multifocal HGPIN on biopsy predicts a higher rate of 
prostate cancer on repeat biopsy than does a single focus 
of HGPIN [13,53,54]. The evidence for this finding has been 
noted in multiple studies, and multifocality has been estab-
lished as a consistent predictor. Roscigno et al. [53] in-
corporated multifocality along with PSA level, age, and ≤
12-core initial biopsy into a nomogram that was 72% accu-
rate in predicting prostate cancer on repeat biopsy. The 
current data on the prognostic value of single versus multi-
ple cores of HGPIN are summarized in Table 1. Studies on 
the rate of subsequent cancer diagnosis in men with 
HGPIN on limited vs. extended vs. saturation biopsy 
schemes are summarized in Table 2.Korean J Urol 2012;53:297-303
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TABLE 1. Extended biopsy schemes and cancer diagnosis in men with HGPIN
Reference N
Cores taken on initial 
biopsy
Cores taken on repeat 
biopsy
Rate of cancer on repeat 
biopsy
Lefkowitz et al. [62]
Moore et al. [63]
Herawi et al. [49]
Eskicorapci et al. [50]
Schoenfield et al. [64]
De Nunzio et al. [65]
Antonelli et al. [66]
Roscigno et al. [53]
Lee et al. [51]
43
33
113
253
23
35
9
33
251
154
108
178
136
12
≥10
6
≥8
6
10
24
12
≥12
≤12
＞12
10
10
≥8
≥8
14
14
≤14
≥20
1/43 (2%)
1/33 (3%)
36/113 (32%)
37/253 (15%)
13/23 (57%)
8/35 (23%)
3/9 (33%)
22/117 (19%)
48/241 (19%)
58/154 (38%)
25/108 (23%)
35/178 (20%)
42/136 (31%)
Multivariate odds ratio 2.2 for increased cancer detection with more cores (≥20 versus ≤14) on re-
peat biopsy in the Lee study
HGPIN, high-grade prostatic intraepithelial neoplasia.
TABLE 2. Multifocal HGPIN and prostate cancer diagnosis
Reference  N
Cores with 
HGPIN
Rate of cancer 
on repeat biopsy
Kronz et al. [13]
Bishara et al. [67]
Netto and Epstein [68]
Akhavan et al. [54]
Schoenfield et al. [64]
De Nunzio et al. [65]
Antonelli et al. [66]
Roscigno et al. [53]
Lee et al. [51]
149
47
10
8
68
64
41
48
48
5
4
33
25
26
33
251
147
115
314
1
2
3
≥4
1
≥2
≥4
1
Any
1
≥2
1
2
3
≥4
＜4
≥4
1
≥2
44/149 (30%)
15.47 (32%)
4/10 (40%)
6/8 (75%)
15/68 (22%)
23/64 (36%)
16/41 (39%)
17%
15/48 (31%)
0/5 (0%)
3/4 (75%)
3/33 (9%)
4/25 (16%)
3/26 (12%)
12/33 (36%)
19%
24%
37/147 (25%)
46/115 (40%)
Multivariate odds ratio 3.2 for 
increased cancer detection 
with multifocal HGPIN
HGPIN, high-grade prostatic intraepithelial neoplasia.
TREATMENT RECOMMENDATIONS
The management of patients with HGPIN depends largely 
on the interpretation of the data presented above. Guide-
lines from the European Association of Urology state that 
“HGPIN as an isolated finding is no longer considered an 
indication for re-biopsy” unless it occurs multifocally [55]. 
The National Comprehensive Cancer Network acknowl-
edges the need for an extended biopsy scheme in their 
guidelines that “recommend a repeat biopsy using an ex-
tended pattern including transition zone if non-focal 
HGPIN is found on a sextant biopsy. If extended biopsies 
were used initially, a delayed strategy (re-biopsy 1 year af-
ter initial biopsy) may be considered” [56]. 
Despite the similar rates of cancer detection in men with 
monofocal HGPIN and benign biopsies, some sources con-
tinue to recommend repeat biopsy at 1 year for such find-
ings [48]. However, we feel that based on the currently 
available data, men with monofocal HGPIN do not need a 
scheduled repeat biopsy, but that the decision for repeat bi-
opsy should be based on standard clinical factors (rising 
PSA, new nodule on DRE, etc). Others also espouse this ap-
proach [18,57]. We also feel that the evidence supports re-
peat biopsy for multifocal HGPIN and for patients who had 
fewer than 10 cores taken on the initial biopsy. Given the 
low correlation between HGPIN and prostate cancer, near-
ly all sources recommend against radical prostatectomy, 
radiation, or androgen deprivation therapy for isolated 
HGPIN.
A number of studies have investigated possible thera-
pies to lower the incidence of HGPIN or to decrease the rate 
of progression from HGPIN to prostate cancer [48]. The 
Prostate Cancer Prevention Trial demonstrated that 7 
years of treatment with daily finasteride decreased the in-
cidence of HGPIN from 7.1 to 6.0% [58]. Similarly, in the 
REDUCE trial, dutasteride reduced the incidence of 
HGPIN from 6.0 to 3.7% [59]. Green tea catechins for 1 year 
in men with HGPIN reduced the incidence of cancer from 
30 to 3% [60]. Soy, vitamin E, and selenium did not slow 
the rate of progression of HGPIN to prostate cancer in a 
randomized double-blind trial in 303 men [61]. We do not 
routinely recommend any of these therapies to men with Korean J Urol 2012;53:297-303
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HGPIN.
CONCLUSIONS
HGPIN is a relatively common finding in prostate biopsies, 
and it has been established as a precursor to prostate 
adenocarcinoma. Its predictive value of increased risk of 
developing future cancer is low when identified in isolation 
or in low volume. However, a repeat biopsy should be 
strongly considered if the initial biopsy contains less than 
10 cores or if the HGPIN is present in large volume and 
within multiple cores. 
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